Anti-SLC17A6 monoclonal antibody
Pre-made anti-SLC17A6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to SLC17A6/SLC17A6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1654-Ab-1/ GM-Tg-hg-IP1654-Ab-2 | Anti-Human SLC17A6 monoclonal antibody | Human |
GM-Tg-rg-IP1654-Ab-1/ GM-Tg-rg-IP1654-Ab-2 | Anti-Rat SLC17A6 monoclonal antibody | Rat |
GM-Tg-mg-IP1654-Ab-1/ GM-Tg-mg-IP1654-Ab-2 | Anti-Mouse SLC17A6 monoclonal antibody | Mouse |
GM-Tg-cynog-IP1654-Ab-1/ GM-Tg-cynog-IP1654-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC17A6 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1654-Ab-1/ GM-Tg-felg-IP1654-Ab-2 | Anti-Feline SLC17A6 monoclonal antibody | Feline |
GM-Tg-cang-IP1654-Ab-1/ GM-Tg-cang-IP1654-Ab-2 | Anti-Canine SLC17A6 monoclonal antibody | Canine |
GM-Tg-bovg-IP1654-Ab-1/ GM-Tg-bovg-IP1654-Ab-2 | Anti-Bovine SLC17A6 monoclonal antibody | Bovine |
GM-Tg-equg-IP1654-Ab-1/ GM-Tg-equg-IP1654-Ab-2 | Anti-Equine SLC17A6 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1654-Ab-1/ GM-Tg-hg-IP1654-Ab-2; GM-Tg-rg-IP1654-Ab-1/ GM-Tg-rg-IP1654-Ab-2; GM-Tg-mg-IP1654-Ab-1/ GM-Tg-mg-IP1654-Ab-2; GM-Tg-cynog-IP1654-Ab-1/ GM-Tg-cynog-IP1654-Ab-2; GM-Tg-felg-IP1654-Ab-1/ GM-Tg-felg-IP1654-Ab-2; GM-Tg-cang-IP1654-Ab-1/ GM-Tg-cang-IP1654-Ab-2; GM-Tg-bovg-IP1654-Ab-1/ GM-Tg-bovg-IP1654-Ab-2; GM-Tg-equg-IP1654-Ab-1/ GM-Tg-equg-IP1654-Ab-2 |
Products Name | Anti-SLC17A6 monoclonal antibody |
Format | mab |
Target Name | SLC17A6 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-SLC17A6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1654-Ag-1 | Recombinant multi-species VGLU2/ SLC17A6/ DNPI protein |
ORF Viral Vector | pGMLPm003004 | mouse Slc17a6 Lentivirus plasmid |
ORF Viral Vector | vGMLPm003004 | mouse Slc17a6 Lentivirus particle |
Target information
Target ID | GM-IP1654 |
Target Name | SLC17A6 |
Gene ID | 57084,140919,84487,100425977,100316859,101098576,100125225,100057463 |
Gene Symbol and Synonyms | 2900073D12Rik,DNPI,SLC17A6,VGLUT2 |
Uniprot Accession | Q9P2U8,Q9JI12,A6QLI1 |
Uniprot Entry Name | VGLU2_HUMAN,VGLU2_RAT,VGLU2_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000091664 |
Target Classification | N/A |
The target: SLC17A6, gene name: SLC17A6, also named as DNPI, VGLUT2. Predicted to enable L-glutamate transmembrane transporter activity and neurotransmitter transmembrane transporter activity. Involved in neurotransmitter loading into synaptic vesicle. Predicted to be located in synaptic vesicle. Predicted to be active in excitatory synapse. Predicted to be integral component of synaptic vesicle membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.